Investigational drug · Phase 2
AZD5462
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "AZD5462"
First trial start
2024
Jun 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5462", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Heart Failure
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5462" as an intervention, largest first.
- A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailurePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06299826 · 375 participants · Start Jun 4, 2024 · Primary completion Feb 10, 2026
Drug: AZD5462; Placebo · For: Chronic Heart Failure
Sites: Alexander City, Alabama; Northridge, California; Torrance, California · 57 sites in all
AstraZenecaAstraZeneca (AZN)
NCT04994106 · 98 participants · Start Jul 27, 2021 · Primary completion Sep 20, 2022
Drug: AZD5462; Placebo · For: Healthy Participants
Sites: Glendale, California
AstraZenecaAstraZeneca (AZN)
NCT05395117 · 32 participants · Start Jun 30, 2022 · Primary completion Sep 12, 2022
Drug: AZD5462; Midazolam and 2 more · For: Healthy Participants
Sites: Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT05512806 · 16 participants · Start Aug 24, 2022 · Primary completion Nov 7, 2022
Drug: AZD5462 · For: Healthy Participants
Sites: Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06661733 · 16 participants · Start Nov 18, 2024 · Primary completion Dec 23, 2024
Drug: AZD5462 · For: Renal Impairment
Sites: Sofia, Bulgaria
AstraZenecaAstraZeneca (AZN)
NCT06989983 · 8 participants · Start May 20, 2025 · Primary completion Jun 25, 2025
Drug: AZD5462 film-coated tablet; [14C]AZD5462 Solution for Infusion and 1 more · For: Heart Failure
Sites: Ruddington, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT06639087 · 8 participants · Start Sep 27, 2024 · Primary completion May 29, 2025
Drug: AZD5462; Dapagliflozin · For: Renal Impairment; Heart Failure
Sites: Sofia, Bulgaria
Newest research
PubMed records naming it or its code names, newest first.
- Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial.
Januzzi JL, Rosenmeier JB, Ely Pizzato P, et al. · Circulation 2026
- Divergent activation of the RXFP1 relaxin receptor by protein and small molecule agonists.
Osei-Owusu J, Girbau T, Wang X, et al. · bioRxiv 2026
- Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design.
Quintana-Hayashi MP, Connolly K, Millegård M, et al. · ESC Heart Fail 2026
- The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans.
Ryberg E, Bergström F, Sten S, et al. · Mol Ther Adv 2026
- A Phase 1b Randomized Clinical Trial of AZD5462 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment.
Quintana-Hayashi MP, Connolly K, Greasley P, et al. · Am J Cardiol 2026
- Liquid Chromatography Combined With Electrospray Ionization Tandem Mass Spectrometry for the Determination and Identification of AZD5462 and Its Metabolites in Rat Plasma.
You C, Zhang Y, Kong D, et al. · Biomed Chromatogr 2025
Also in development for Chronic Heart Failure
- JTT-861Phase 21 trial
Shionogi Inc. · Chronic Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.